New: Introducing the Finviz Crypto Map

Learn More

Jefferies Reiterates a Buy Rating on Boston Scientific Corporation (BSX), Sets a $130 PT

By Noor Ul Ain Rehman | August 15, 2025, 9:43 PM

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in for beginners. In a report released on August 11, Matthew Taylor from Jefferies reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $130.00.

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?
A surgeon examining a patient's brain in an operating room, paramedics nearby.

The rating update followed the company’s release of fiscal Q2 2025 earnings on July 23, with net sales for the quarter reaching $5.061 billion and reflecting a 22.8% growth on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis, all compared to the prior year period.

Boston Scientific Corporation (NYSE:BSX) also reported GAAP net income attributable to common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News